The debt facility reduces near-term funding risk and supports pipeline execution. Monitor upcoming FDA decisions on biosimilar BLAs (AVT05, AVT06, AVT16) as key catalysts. The high interest cost adds leverage, so progress on approvals is critical.
Price Chart
Executive Summary
Alvotech secured a $75 million term loan facility from GoldenTree Asset Management, adding to a recent $165 million equity raise for total new capital access of $240 million. The loan carries a 12.5% interest rate and matures Dec 31, 2027, strengthening liquidity for biosimilar pipeline and launches.
Key Facts
- Additional $75 million term loan facility announced on July 1, 2026.
- Loan matures December 31, 2027, with 12.50% cash interest payable monthly.
- Follows $165 million equity raise from June 18, 2026; total new capital access of $240 million.
- Loan provided by funds managed by GoldenTree Asset Management LP, existing lender to Alvotech.
Financial Impact
$75 million additional debt at 12.5% interest, raising total new capital access to $240 million including prior equity raise. Alvotech market cap ~$1.2B, so facility is ~6.25% of market cap.
Risk Factors
- High interest cost (12.5%) increases fixed charges.
- Increased debt burden may limit future financing flexibility.
- Alvotech still pre-revenue with $2.41B accumulated deficit; relies on continued capital access.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004413 |
| Document: f6k_070126.htm | 0001171843-26-004413 |
| Document: 0001171843-26-004413-index-headers.html | 0001171843-26-004413 |
| Document: 0001171843-26-004413-index.html | 0001171843-26-004413 |
| Document: 0001171843-26-004413.txt | 0001171843-26-004413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $5.12 | awaiting T+20 | — | $4.62 (−9.77%) |
Oct 14, 2026 12d ago | 6-K | $5.17 | awaiting T+20 | — | $4.62 (−10.64%) |
Oct 7, 2026 19d ago | 6-K | $5.85 | awaiting T+20 | — | $4.62 (−21.03%) |
Oct 5, 2026 21d ago | 6-K | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Oct 5, 2026 21d ago | Press Release | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.62 (−10.98%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.62 (+4.29%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.62 (−8.20%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.62 (+30.88%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.62 (+33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers